RHJA
NVCR icon

Rice Hall James & Associates’s NovoCure NVCR Stock Holding History

Rice Hall James & Associates’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,215
Closed -$733K – 291
2019
Q1 		$733K Buy
15,215
+600
+4% +$28.9K 0.02% 259
2018
Q4 		$489K Sell
14,615
-72
-0.5% -$2.63K 0.02% 266
2018
Q3 		$770K Buy
14,687
+5,100
+53% +$203K 0.03% 259
2018
Q2 		$300K Buy
+9,587
New +$267K 0.01% 282

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Rice Hall James & Associates's NVCR Position: Q2 2019 in Review

Rice Hall James & Associates sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 15,215 shares — an estimated $733K sold.

Rice Hall James & Associates first reported a position in NVCR in Q2 2018 and held it in 4 quarters. The position peaked at $770K in Q3 2018. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

  • Rice Hall James & Associates reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
  • Rice Hall James & Associates sold 15,215 NovoCure shares in Q2 2019, an estimated $733K.
  • Rice Hall James & Associates first reported a position in NovoCure in Q2 2018 and held it in 4 quarters.
  • Rice Hall James & Associates's NovoCure position peaked at $770K in Q3 2018.
  • 197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on Rice Hall James & Associates's 13F filing for Q2 2019, filed 1 Aug 2019.